Search Records

Pets can provide many benefits, especially during times of stress. However, during the COVID-19 pandemic, special consideration should be given to animals that reside in or visit long-term care homes (LTCHs), where COVID-19 may transmit more easily and people are at risk of more severe disease....

A list of pharmacies authorized to distribute rapid antigen test kits to small and medium organizations.

The government of Canada is providing access to COVID-19 Rapid Tests. To find out how your workplace can order free rapid tests visit Canada.ca/covid-workplace-testing.

Vaccines are essential to help end the pandemic. It's important for everyone to get vaccinated against COVID-19 when it's their turn. Vaccines help lower your child's risk of infection. They work with the body's natural defenses to develop protection against a disease. Being vaccinated will...

COVID-19 vaccines must be manufactured under good manufacturing practices (GMP) conditions. These conditions must be in line with international requirements, which are outlined in the International Council for Harmonization Q7A guideline and applicable Health Canada guidance.

Decisions made about COVID-19 vaccines will follow processes established for reviews under the modified requirements for COVID-19 drugs. Health Canada will start rolling reviews to build towards a complete dossier for each vaccine. The dossier will include data to support the safety, efficacy and...

This document will help manufacturers prepare a submission for a notice of compliance for a COVID-19 drug under the Regulations. It also outlines the process for meeting the post-market regulatory requirements.

The Governor in Council introduced amendments to the Regulations to provide a mechanism for COVID-19 drugs to be authorized through the issuance of an NOC, based on modified requirements that have been transferred from the ISAD IO.

Division 1A of Part C of the Regulations applies to COVID-19 drugs. A person must hold a drug establishment licence (DEL) authorizing any activities conducted with respect to COVID-19 drugs.

The only amendment related to post-market regulation is the Minister’s new (continued) authority to impose terms and conditions for a designated COVID-19 drug (C.01.014.21).